Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclax-Reference-Cited by-同舟云学术

Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclax

Published:2015-09 Issue:5 Volume:3 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Ackler Scott¹,Oleksijew Anatol¹,Chen Jun¹,Chyla Brenda J.¹,Clarin Jerry¹,Foster Kelly¹,McGonigal Thomas¹,Mishra Sasmita¹,Schlessinger Sally¹,Smith Morey L.¹,Tahir Stephen K.¹,Leverson Joel D.¹,Souers Andrew J.¹,Boghaert Erwin R.¹,Hickson Jonathan¹

Affiliation:

1. AbbVie Inc. North Chicago Illinois

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.178

Reference27 articles.

1. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

2. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumoursin vivo

3. Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia

4. Chronic Lymphocytic Leukemia

5. The Bcl‐2‐specific BH3‐mimetic ABT‐199 (GDC‐0199) is active and well‐tolerated in patients with relapsed non‐Hodgkin lymphoma: interim results of a phase I study;Davids MS;Blood (ASH Annual Meeting Abstracts),2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients;Communications Medicine;2023-10-25

2. Anti-cancer peptides: their current trends in the development of peptide-based therapy and anti-tumor drugs;Biotechnology and Genetic Engineering Reviews;2022-06-14

3. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia;Blood Advances;2021-12-10

4. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung;Cell Death & Disease;2021-06

5. Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL;mAbs;2021-01-01